Sustained EKR inhibition by EGFR targeting therapies is a predictive factor for synergistic cytotoxicity with PDT as neoadjuvant therapy
Authors:
- Anette WeyergangAnette Weyergang
- Pål K. SelboPål K. Selbo
- Kristian BergKBKristian Berg
- 1 March 2013
- journal article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1830 (3) , 2659-2670
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Anti‐EGFR Monoclonal Antibodies for Treatment of Colorectal Cancers: Development of Cetuximab and PanitumumabThe Journal of Clinical Pharmacology, 2012
- EGFR targeting drugs in the treatment of head and neck squamous cell carcinomaExpert Opinion on Emerging Drugs, 2010
- Therapeutic targeting of EGFR in malignant gliomasExpert Opinion on Therapeutic Targets, 2010
- Factors underlying sensitivity of cancers to small-molecule kinase inhibitorsNature Reviews Drug Discovery, 2009
- EGFR Antagonists in Cancer TreatmentNew England Journal of Medicine, 2008
- Strategies for optimizing combinations of molecularly targeted anticancer agentsNature Reviews Drug Discovery, 2006
- Avastin Enhances Photodynamic Therapy Treatment of Kaposi's Sarcoma in a Mouse Tumor ModelJournal of Environmental Pathology, Toxicology and Oncology, 2006
- Targeting epidermal growth factor receptor: novel therapeutics in the management of cancerExpert Review of Anticancer Therapy, 2003
- Photodynamic therapy for cancerNature Reviews Cancer, 2003
- Photodynamic TherapyJNCI: Journal of the National Cancer Institute, 1998